Solid revenue stream from European business driven by

  • Innovative, convenient and patient friendly (short course) products
  • Focused investment across the business, reflective in performance
  • Strength of broad portfolio with Modified Mite and venom SCIT
  • Best in class commercial and sales teams
  • 10% CAGR growth over the 19 years since the Company formed

Strong pipeline

  • Highly positive results achieved from Grass Phase II trial
  • Modified Mite: Short course product with global potential
  • Positive results achieved from pre-clinical peanut SCIT product (Peanut represents a new opportunity into the $8billion worldwide food allergy market)

Preparing for US Entry

  • $2billion estimated allergy immunotherapy market
  • $300 – 400 million estimated peak grass sales
  • No registered injectable products in the US
  • Portfolio of products offer a strategic advantage to capture US market